David James Bearss

US Patent:

7312226, Dec 25, 2007

Filed:

Mar 29, 2005

Appl. No.:

11/092168

Inventors:

Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Steven L. Warner - Tucson AZ, US

Assignee:

Arizona Board of Regents on Behalf of The University of Arizona - Tucson AZ
Montigen Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

A61K 31/519
C07D 487/14
A61P 35/00

US Classification:

514267, 544250

Abstract:

Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:.

US Patent:

7326712, Feb 5, 2008

Filed:

Oct 14, 2004

Appl. No.:

10/965313

Inventors:

Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Highland UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Steven L. Warner - Tucson AZ, US

Assignee:

Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ
Supergen, Inc. - Dublin CA

International Classification:

C07D 471/14
A61K 31/519
A61P 35/04
C07D 239/70
A61K 31/517

US Classification:

514267, 544250, 544283, 544284, 544293, 5142661, 5142662, 51426624

Abstract:

Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:.

US Patent:

7326713, Feb 5, 2008

Filed:

Mar 29, 2005

Appl. No.:

11/092809

Inventors:

Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Steven L. Warner - Tucson AZ, US

Assignee:

Arizona board of Regents on Behalf of the University of Arizona - Tucson AZ
Montigen Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

A61K 31/519
C07D 487/14
A61P 35/00

US Classification:

514267, 544250

Abstract:

Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:.

US Patent:

7335662, Feb 26, 2008

Filed:

Mar 29, 2005

Appl. No.:

11/092863

Inventors:

Laurence H. Hurley - Tucson AZ, US
Daruka Mahadevan - Tucson AZ, US
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Salt Lake City UT, US
Sridevi Bashyam - Tucson AZ, US
Steven L. Warner - Tucson AZ, US

Assignee:

Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ
Montigen Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

A61K 31/519
C07D 487/14
A61P 35/00

US Classification:

514267, 544250

Abstract:

Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:.

US Patent:

7750007, Jul 6, 2010

Filed:

Nov 6, 2007

Appl. No.:

11/935959

Inventors:

David J. Bearss - Cedar Hills UT, US
Xiao-Hui Liu - Sandy UT, US
Hariprasad Vankayalapati - Draper UT, US
Yong Xu - Midvale UT, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K 31/5025
A61K 31/519
C07D 413/12
C07D 487/04
A61K 31/5375
A61P 35/00

US Classification:

514248, 544236, 544281, 544117, 544224

Abstract:

The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II):.

US Patent:

7790746, Sep 7, 2010

Filed:

Dec 18, 2007

Appl. No.:

11/959181

Inventors:

Pasit Phiasivongsa - Brentwood CA, US
Sanjeev G. Redkar - Hayward CA, US
Swarna Gamage - Mt Roskill, NZ
Darby Brooke - Waterview, NZ
William Denny - Pakuranga, NZ
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K 31/47

US Classification:

514313, 546162

Abstract:

Quinoline derivatives, particularly 4-anilinoquinoline derivatives of formula (I), are provided:.

US Patent:

7820684, Oct 26, 2010

Filed:

Mar 3, 2008

Appl. No.:

12/041565

Inventors:

David J. Bearss - Cedar Hills UT, US
Rajashree Joshi-Hangal - Pleasanton CA, US
Xiao-Hui Liu - Sandy UT, US
Pasit Phiasivongsa - Brentwood CA, US
Sanjeev G. Redkar - Hayward CA, US
Hariprasad Vankayalapati - Draper UT, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A01N 43/54
A61K 31/505

US Classification:

514267

Abstract:

The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

US Patent:

7939546, May 10, 2011

Filed:

Apr 10, 2009

Appl. No.:

12/422067

Inventors:

Pasit Phiasivongsa - Brentwood CA, US
Sanjeev G. Redkar - Hayward CA, US
Swarna Gamage - Mt Roskill, NZ
Darby Brooke - Waterview, NZ
William Denny - Pakuranga, NZ
David J. Bearss - Cedar Hills UT, US
Hariprasad Vankayalapati - Draper UT, US
Yong Xu - Midvale UT, US
Krzysztof Swierczek - West Jordan UT, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K 31/47

US Classification:

514313, 546161, 546242, 548541

Abstract:

Quinoline derivatives, particularly 4-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine-2-carboxylic acid; 3-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine; N-(4-(piperidin-4-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide; and N-(4-(piperidin-3-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide, or a physiologically acceptable salt thereof, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.